To: Harry Feliciano, MD, MPH, Senior Medical Director, Palmetto GBA
"As further advances are made in this technology, it is important that more CGM options be made available to patients with diabetes. The Endocrine Society recommends CGM systems as the gold standard for managing type 1 diabetes, and the technology also can be useful for some people with type 2 diabetes. CGMs are also included in the American Diabetes Association’s (ADA) Standards of Medical Care for the treatment of patients with diabetes who require insulin. The Standards state that “when used properly, real-time continuous glucose monitors in conjunction with intensive insulin regiments is a useful tool to lower A1c in adults with type 1 diabetes who are not meeting glycemic targets.” The Standards also recommend that real-time CGMs be used on a daily basis if possible, for maximum benefit to the patient."
Read the Full Letter 
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.